Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Promoting coronavirus disease 2019 (COVID-19) vaccination
among healthcare personnel: A multifaceted intervention at a
tertiary-care center in Japan
Akane Takamatsu
Tokyo Metropolitan Tama Medical Center

Hitoshi Honda
Tokyo Metropolitan Tama Medical Center

Tomoya Kojima
Tokyo Metropolitan Tama Medical Center

Kengo Murata
Tokyo Metropolitan Tama Medical Center

Hilary M Babcock
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Takamatsu, Akane; Honda, Hitoshi; Kojima, Tomoya; Murata, Kengo; and Babcock, Hilary M, ,"Promoting
coronavirus disease 2019 (COVID-19) vaccination among healthcare personnel: A multifaceted
intervention at a tertiary-care center in Japan." Infection Control & Hospital Epidemiology. ,. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10497

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Infection Control & Hospital Epidemiology (2021), 1–6
doi:10.1017/ice.2021.325

Original Article

Promoting coronavirus disease 2019 (COVID-19) vaccination among
healthcare personnel: A multifaceted intervention at a tertiary-care
center in Japan
Akane Takamatsu MD1,2, Hitoshi Honda MD, PhD1,2

, Tomoya Kojima MSc2, Kengo Murata MD3 and

Hilary M. Babcock MD, MPH4
1

Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 2Department of Infection Control, Tokyo Metropolitan Tama Medical
Center, Tokyo, Japan, 3Department of Respiratory and Medical Oncology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan and 4Division of Infectious
Diseases, Washington University School of Medicine, St. Louis, Missouri, United States

Abstract
Objective: The coronavirus disease 2019 (COVID-19) vaccine may hold the key to ending the pandemic, but vaccine hesitancy is hindering the
vaccination of healthcare personnel (HCP). We examined their perceptions of the COVID-19 vaccine and implemented an intervention to
increase vaccination uptake.
Design: Before-and-after trial.
Participants and setting: Healthcare personnel at a 790-bed tertiary-care center in Tokyo, Japan.
Interventions: A prevaccination questionnaire was administered to HCP to examine their perceptions of the COVID-19 vaccine. A multifaceted intervention was then implemented involving (1) distribution of informational leaflets to all HCP, (2) hospital-wide announcements
encouraging vaccination, (3) a mandatory lecture, (4) an educational session about the vaccine for pregnant or breastfeeding HCP, and (5)
allergy testing for HCP at risk of allergic reactions to the vaccine. A postvaccination survey was also performed.
Results: Of 1,575 HCP eligible for enrollment, 1,224 (77.7%) responded to the questionnaire, 533 (43.5%) expressed willingness to be vaccinated, 593 (48.4%) were uncertain, and 98 (8.0%) expressed unwillingness to be vaccinated. The latter 2 groups were concerned about the
vaccine’s safety rather than its efficacy. After the intervention, the overall vaccination rate reached 89.7% (1,413 of 1,575), and 88.9% (614 of
691) of the prevaccination survey respondents answered “unwilling” to or “unsure” about eventually receiving a vaccination. In the postvaccination questionnaire, factors contributing to increased COVID-19 vaccination included information and endorsement of vaccination at the
medical center (274 of 1,037, 26.4%).
Conclusions: This multifaceted intervention increased COVID-19 vaccinations among HCP at a Japanese hospital. Frequent support and
provision of information were crucial for increasing the vaccination rate and may be applicable to the general population as well.
(Received 18 May 2021; accepted 28 June 2021)

Coronavirus disease 2019 (COVID-19) was first reported in
Wuhan, China, in late December 2019. Since then, COVID-19
has rapidly spread worldwide and has resulted in > 3.1 million
deaths.1 Although the number of new cases has been declining,
COVID-19 is still a significant burden throughout the world.
Currently, >1.0 billion doses of the COVID-19 vaccine, which is
considered the most promising way of ending the pandemic, have
been administered in >180 countries.1 In Japan, the Minister of
Health, Labour, and Welfare is overseeing vaccine distribution,
and the mRNA-based severe acute respiratory coronavirus virus
2 (SARS-CoV-2) vaccine manufactured by Pfizer/BioNTech was
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approved for use in Japan on February 14, 2021. The Japanese government is strongly recommending citizens to receive COVID-19
vaccination and has announced plans to provide vaccinations to all
individuals aged ≥16 years free of charge.2 Healthcare personnel
(HCP), considered a high-priority group, were the first to begin
receiving their vaccinations beginning on February 17, 2021.
Although the COVID-19 vaccine is reportedly effective, few
data are available regarding associated adverse events among
Asian populations,3,4 and many nations in Asia have adopted a
cautious stance resulting in rollout lags. The public’s lack of familiarity with the new, mRNA-based vaccine may be stirring vaccine
skepticism.5,6 Moreover, Japan’s relatively low cumulative number
of confirmed infections and COVID-19–related mortality rate
compared with those of Europe and North and South America,1
as well as religious and cultural considerations, may be contributing to vaccine hesitancy among the Japanese.7,8 A recent study
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Fig. 1. Timeline from preinterventional to postvaccination questionnaire survey. Note. HCP, healthcare personnel.

reported that HCP also felt hesitant about receiving the COVID-19
vaccine.9 In the present study, we investigated the current attitudes
toward COVID-19 vaccination among HCP at a Japanese tertiarycare center, and we evaluated the impact of a multifaceted intervention on the vaccination uptake rate in this population.
Methods
Study design and setting
The present interventional study was conducted from January
2021 to March 2021 at Tokyo Metropolitan Tama Medical
Center, a 790-bed tertiary-care center with 34 subspecialties in
Tokyo, Japan, including a division of infectious diseases, department of infection control, and an occupational health and safety
committee. The latter organized a COVID-19 vaccination program
for HCP at the study center, which does not mandate COVID-19
vaccination for its HCP but strongly recommends complying with
the Japanese government’s promotion of COVID-19 vaccination.2
Each HCP at the study center had access to Groupware (Cybozu,
Tokyo, Japan), which was used for hospital-wide communication
(eg, intranet e-mailing), e-learning, and administering surveys.
The study center has been admitting patients with COVID-19,
including critically ill patients, since February 2020, and by
April 2021, >850 patients with the disease were admitted.
Participants
All healthcare personnel directly employed by the study center (ie,
physicians, registered nurses, nursing aides, pharmacists, other
allied health professionals, and administrative personnel) were
included. HCP with part-time status were excluded because their
vaccine schedule was determined by their primary employer. The

institutional review board at the study institution approved
this study.
Prevaccination questionnaire survey
A prevaccination questionnaire survey, consisting of 6 items asking
about the respondents’ perception of the COVID-19 vaccine, was
conducted using the e-learning system. HCP were required to
answer all the items once they started the questionnaire.
Supplementary Table 1 (online) shows the details of the questionnaire items. The respondents were assured that their information
would be kept confidential. To improve the response rate, multiple
reminders from the infection control department were delivered
via intranet e-mail to all HCP, and a telephone call was placed
to each department manager during the survey period (Fig. 1).
Intervention
A multifaceted intervention was conducted by the department of
infection control and occupational health and safety committee.
Figure 1 shows the intervention timeline. After the prevaccination
questionnaire survey period, all HCP received a double-sided,
color leaflet in Japanese with information on the COVID-19 vaccine and answers to frequently asked questions, such as (1) an
explanation of the mRNA vaccine, (2) current evidence of its
safety, efficacy, and common adverse events, (3) vaccinations for
HCP with allergies and pregnant HCP, (4) the cost of vaccination,
and (5) general information about COVID-19 (Supplementary
Fig. 1 online). Posters promoting COVID-19 vaccination were displayed in employee lounges and at the hospital entrance. In addition, a vaccine recommendation was sent to all HCP by the hospital
vice president by e-mail, and a mandatory, e-learning–based
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lecture on the COVID-19 vaccine was provided. An educational
session about vaccinations for pregnant and lactating HCP, an outpatient clinic for allergy testing, and consultation on the COVID19 vaccine ingredients (eg, polyethylene glycol) were provided for
HCP who were interested.
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Table 1. Characteristics of Respondents to Prevaccination Questionnaire
Survey (N = 1,224)
Characteristics
Demographics and general information
Age, median y (range)

Vaccination
The first wave of vaccinations was provided from March 8 to 19,
2021, at a large lecture hall at the study center. The Pfizer/
BioNTech COVID-19 vaccine was available only during the study
period. When HCP willingness to be vaccinated was confirmed,
and after the vaccination, HCP were carefully observed for at least
15 minutes on site in case any critical adverse events occurred.
Postvaccination questionnaire survey
A postvaccination survey was administered in the same manner as
the prevaccination survey (Fig. 1). The questionnaire consisted of
12 questions, including questions on the efficacy of each intervention, the incidence of adverse events within 48 hours and 7 days
after vaccination, and the vaccine recipients’ impression of the vaccination process (Supplementary Table 2 online).
Statistical analysis
The HCP characteristics, vaccine-related adverse events, assessment of each intervention, vaccination acceptance rate in the prevaccination questionnaire survey, actual immunization rate after
intervention, and factors determining vaccination uptake were
summarized using frequencies and percentages. Vaccination
acceptance status (willing vs unwilling or unsure) and reasons
for hesitation in receiving the vaccination (unwilling vs unsure)
were compared. Categorical variables were compared using the
χ2 test or Fisher exact test as appropriate, and continuous variables
were compared using the Mann-Whitney U test. All tests for significance were 2-tailed, and P < .05 was considered to indicate statistical significance. All analyses were performed using SPSS version
25 software (IBM, Armonk, NY) and Stata version 15 software
(StataCorp, College Station, TX).
Results
In total, 1,576 HCP were included; of these, 1,224 HCP (77.7%)
answered the prevaccination questionnaire. Table 1 summarizes
the characteristics of the respondents; 671 (54.8%) of the respondents thought it likely that they would contract COVID-19 in the
future, and 691 (56.5%) responded that they were unwilling or
unsure about being vaccinated. On univariate analyses, factors
associated with a willingness to be vaccinated among HCP were
physician occupation (odds ratio [OR], 3.67; 95% confidence interval [CI], 2.56–5.28), male sex (OR, 3.25; 95% CI, 2.49–4.24), and
increasing age (OR, 1.01; 95% CI, 1.00–1.02) (Table 2). Despite our
concern about an interaction between sex and occupational status
(physicians vs nurses) due to the preponderance of female nurses,
we detected no significant difference in the vaccine acceptance
rates between female physicians and female nurses: 53 (65.4%)
of 81 physicians versus 160 (29.1%) of 549 nurses (P < .001).
Table 3 lists the reasons for hesitation. HCP who responded that
they were unsure about or unwilling to be vaccinated appeared to
have a number of concerns regarding vaccination, and the degree
of each concern in the latter group was higher than that in the former. The main concern in both groups was the safety rather than
the efficacy of the vaccine.

No. (%)

40 (21–72)

Sex, no. (%)
Male

320 (26.1)

Female

904 (73.9)

Occupation, no. (%)
Physician

236 (19.3)

Nurse

641 (52.4)

Nursing aide

28 (2.3)

Pharmacist

47 (3.8)

Laboratory technician

51 (4.2)

Clinical engineer

16 (1.3)

Radiological technician

46 (3.8)

Physical therapist

26 (2.1)

Nutritionist
Social worker
Desk officer
Others
No. of household members (including respondents),
median (range)
Influenza vaccination in 2020–2021 season, no. (%)

8 (0.7)
14 (1.1)
103 (8.4)
8 (0.7)
3 (1–11)
1,179 (96.3)

Self-assessed overall health, no. (%)
Good

669 (54.7)

Fair

535 (43.7)

Poor

20 (1.6)

Perception of COVID-19 and COVID-19 vaccination
Possibility of contracting COVID-19 in future, no. (%)
Yes – I think I will get a serious case of COVID-19.

147 (12.0)

Yes – I think I will get a mild case of COVID-19.

524 (42.8)

No – I don’t think I will get COVID-19.

549 (44.9)

I already had COVID-19 prior to the questionnaire.

4 (0.3)

Willingness to receive COVID-19 vaccine, no. (%)
Willing (Yes)
Unwilling (No)
Unsure (Not sure)

533 (43.5)
98 (8.0)
593 (48.4)

The overall vaccination uptake rate at the study center reached
89.7% (1,413 of 1,575), which was substantially higher than the proportion expressing willingness to receive the vaccine before the intervention. Vaccination uptake among the 1,224 HCP who responded to
the prevaccination questionnaire survey reached 92.1% (1,127 of
1,224). Of the 691 respondents who were unwilling or unsure before
the intervention, 614 (88.9%) subsequently accepted vaccination. Of
the 98 who responded “unwilling,” 66 (67.3%) subsequently accepted
vaccination, and of the 593 who responded “unwilling, 513 (92.4%)
subsequently accepted vaccination. Supplementary Table 3 (online)
shows the details of the vaccination rate.
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Table 2. Comparison of Vaccine Acceptance by Demographic Information in the Prevaccination Survey (n = 1,224)
Vaccination Acceptance Status
Variables

Unwilling or Unsure
(n=691)

Willing (n=533)

Odds Ratio (95% CI)

Occupational status, no. (%)
Others

156 (29.3)

191 (27.6)

Referance

Physicians

177 (33.2)

59 (8.5)

3.67 (2.56–5.28)

Nurses

200 (37.5)

441 (63.8)

0.56 (0.42–0.73)

Female

326 (61.2)

578 (83.6)

Reference

Male

207 (38.8)

113 (16.8)

3.25 (2.49–4.24)

Sex, no. (%)

Age, median (IQR), years

42 (30–51)

40 (30–49)

1.01 (1.00–1.02)

Note. IQR, interquartile range; CI, confidence interval.

Table 3. Comparison of Reasons for Vaccine Hesitancy by Acceptance Status in the Prevaccination Survey (n = 1,224)
Vaccination Acceptance Status
Willing (n=533)

Unsure (n=593)

Unwilling
(n=98)

1. I’m concerned about the side effects or adverse reactions (vaccine safety) to the COVID-19 vaccine.

5 (0.9)

492 (83.0)

1 (92.9)

2. I’m not sure that the new COVID-19 vaccine is effective at all.

2 (0.4)

186 (31.4)

1 (41.8)

3. I’m not sure that the new COVID-19 vaccine is effective against SARS-CoV2 variants.

2 (0.4)

170 (28.7)

1 (40.8)

4. I don’t want to be a test subject for the new COVID-19 vaccine.

0 (0)

159 (26.8)

1 (42.9)

Reasons (Multiple Answers Allowed), No. (%)

5. I don’t know what’s contained in the new COVID-19 vaccine.

0 (0)

122 (20.6)

1 (22.8)

6. General information about the new COVID-19 vaccine is insufficient.

2 (0.4)

289 (48.7)

1 (59.2)

7. I’m nervous about getting the new COVID-19 vaccination because I have (an) underlying illness(es).

0 (0)

54 (9.1)

1 (9.2)

8. I have a history of adverse reactions to vaccinations.

0 (0)

21 (3.5)

1 (11.2)

9. I have food or drug allergies.

0 (0)

71 (12.0)

1 (14.3)

10. I don’t need the vaccination because the symptoms of COVID-19 are usually mild.

0 (0)

14 (2.4)

4 (4.1)

11. I’m generally skeptical of vaccines.

1 (0.2)

87 (14.7)

25 (25.5)

12. I feel that mass media coverage is against vaccination.

0 (0)

17 (2.9)

2 (2.0)

13. I don’t trust the Japanese government’s information about vaccine distribution.

0 (0)

82 (13.8)

23 (23.5)

14. I’m skeptical of the pharmaceutical companies that make vaccines.

0 (0)

52 (8.8)

15 (15.3)

15. I think other people have a higher priority for receiving the new COVID-19.

0 (0)

75 (12.6)

12 (12.2)

In total, 1,037 HCP (65.7%) responded to the postvaccination
questionnaire. Among them, 915 HCP (88.2%) felt that the distribution of the informational leaflets was the most effective method of promoting COVID-19 vaccination, and 873 (84.2%) felt that the
e-learning opportunity was the most effective method of promoting
COVID-19 vaccination (Supplementary Fig. 2 online). The most
important factor leading to vaccination acceptance was the fear of
contracting COVID-19 (295 of 1,037, 28.4%) followed by the information about and endorsement of vaccination at the study center (274
of 1,037, 26.4%) (Table 4). In the postvaccination questionnaire, 620
of HCP (59.8%) responded that the administration of COVID-19 vaccination was satisfactory, and 716 (69.1%) responded that they would
recommend vaccination to their close family members and friends.
Common adverse reactions following the first vaccination included
(1) local pain at the injection site within 48 hours of administration
(814 of 1,037, 78.5%) and (2) persistent local pain at the injection site
at 7 days (311 of 1,037, 30%).

Discussion
In this study, we ascertained current perceptions among HCP
toward COVID-19 vaccination. Implementation of our multifaceted intervention changed the perception of COVID-19 vaccination among HCP and resulted in a higher vaccination rate. A
detailed questionnaire survey before and after the intervention
revealed the factors that contributed to either promoting or hindering vaccination among HCP.
Vaccine hesitancy is a potentially serious obstacle to improving
the vaccination rate among any given population. In the present
study, fewer than half of the HCP responding to the preintervention survey were willing to be vaccinated. Studies in various countries around the world have reported an unwillingness among HCP
to be vaccinated despite the significant risk of COVID-19 among
those working at the frontline.6,9–12 Furthermore, this tendency
varied demographically, and ethnicity, age, gender, educational
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Table 4. Single Most Important Factor Leading to Receiving the COVID-19
Vaccination in the PostVaccination Survey (Multiple Answers Not Allowed)
(n =1,037)
Factors

No. (%)

Information and endorsement of vaccination at the study
center (eg, leaflets and e-learning)

274 (26.4)

Self-collected information via news and websites

149 (14.4)

Discussion with colleagues

58 (5.6)

Discussion with supervisor

11 (1.1)

Discussion with family

55 (5.3)

Peer pressure at workplace
Fear of contracting COVID-19

77 (7.4)
295 (28.4)

Anticipation of resuming activities (eg, travel)

39 (3.8)

No specific reasons

61 (5.9)

Not applicable (because I decided not to get vaccinated)

18 (1.7)

status, and previous experience of COVID-19 care significantly
influenced attitudes.5,6,9,13,14 In the present study, female sex, nursing occupation, and younger age were factors associated with lower
willingness to be vaccinated, which is in line with the findings of
previous studies.6,10–12 However, the root cause of their unwillingness lay in each individual’s calculation of the perceived benefits
and risks of vaccination.
Under a voluntary vaccination policy, improving the vaccination rate among HCP requires considerable effort, mainly because
the recently released mRNA vaccine is still unfamiliar to many
people even in healthcare services, and various facts, such as the
long-term effects and potential adverse reactions to COVID-19
vaccines in general are not clearly understood. On an individual
level, vaccine hesitancy might be influenced by religious reasons
(eg, non-halal components in vaccines) and cultural considerations (eg, predominance of pseudoscientific beliefs and antivaccine
conspiracy theories).7 Moreover, skepticism regarding the
COVID-19 vaccine among the HCP stemmed from insufficient
information, which has also been demonstrated by previous studies.5,6,9–11 In addition, insufficient information about the risks to
particular populations, such as pregnant and lactating women,4
contributed to vaccine hesitancy, and general uncertainty was
compounded by misinformation on social media.15,16 Despite these
challenging circumstances, our multifaceted intervention achieved
a high COVID-19 vaccine uptake rate among the HCP at the study
institution. The pre- and postvaccination survey results demonstrated that at each stage of the intervention, providing transparent
and scientifically accurate information on the COVID-19 vaccine
appeared to be effective in encouraging HCP to get vaccinated.
Repeated dissemination of evidence-based information about
the COVID-19 vaccine by various means, including leaflets, poster
campaigns, and e-learning, was likely to have improved awareness
about the vaccine itself, diminishing skepticism and promoting
acceptance. Moreover, special educational lectures targeting
HCP with special concerns, such as pregnant women, and pre-vaccination allergy testing for those worried about potential allergic
reactions, may contribute to promoting vaccination safety, which,
as stated previously, was a greater concern than vaccine efficacy
among most of the HCP polled in the prevaccination survey.
The results of this study also revealed that the concept of

hospital-wide nudge approaches with a multilevel intervention
are essential to increasing the COVID-19 vaccine uptake rate.17–19
Although we achieved a COVID-19 vaccine uptake rate of
almost 90% among HCP at the study center, an even higher vaccine
uptake rate can potentially be achieved. A mandatory vaccine policy is another possible strategy for achieving a high vaccine uptake
rate.20 In Italy, COVID-19 vaccination has become mandatory for
HCP21; however, mandatory vaccination raises ethical and legal
concerns about individual autonomy. Recent surveys of HCP demonstrated poor support for a policy of mandatory COVID-19 vaccination.10,22 Nonetheless, mandating vaccination may be more
acceptable among HCP if an annual COVID-19 booster becomes
the norm.23
Notably, more than two-thirds of the HCP at the study center
responded that they would recommend COVID-19 vaccination to
close family members and friends. A previous study revealed that
positive attitudes among HCP toward vaccination may positively
impact the vaccine uptake rate in the general public.24 Some individuals relied on information from their primary physician and
cited their physician’s recommendations as their reason for being
vaccinated.25 Improving HCP satisfaction with COVID-19 vaccination may help optimize the vaccination effort. Moreover, strong
messages from vaccinated HCP highlighting the personal benefits
of vaccination as well as the importance of the concept of altruistic
or prosocial behavior may help increase the COVID-19 vaccination rate in the general public.19
The present study has several limitations. It was conducted at a
single, Japanese institution, and although the interventions tested
substantially increased the overall COVID-19 vaccination rate,
they may not apply to other healthcare settings. We were unable
to test the differences in the efficacy of the multifaceted intervention in various ethnic groups or individuals of other cultural backgrounds because nearly all the HCP at the study center are of
Japanese ethnicity. Moreover, HCP may not have had enough time
to consider fully the information provided because the time from
the implementation of the prevaccination questionnaire to vaccination was relatively brief. Third, a response bias may have been
introduced because the questionnaire depended entirely on selfreporting. Finally, we were unable to conclude whether the vaccination rate was increased solely by the multifaceted intervention
given the nature of a before-and-after trial.
In summary, a certain number of HCP were cautious about
COVID-19 vaccination, with the chief concern being the safety
of the vaccine. The present study revealed that a multifaceted intervention consisting of a supportive, informative approach is critically important for promoting COVID-19 vaccination among
HCP. This strategy may also be applied to the general population
to enhance their vaccination rate. Because HCP can play a key role
in vaccine promotion, increasing vaccine literacy among them can
positively impact the adoption of successful immunization policies
for the general public.
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